Publication:
Re‐infection in COVID‐19: Do we exaggerate our worries?

dc.contributor.coauthorArslan, Yusuf
dc.contributor.coauthorAkgül, Fethiye
dc.contributor.coauthorSevim, Bünyamin
dc.contributor.coauthorVarol, Zeynep Sedef
dc.contributor.kuauthorTekin, Süda
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid42146
dc.date.accessioned2024-11-10T00:09:48Z
dc.date.issued2022
dc.description.abstractBackground Protective long-term immunity following coronavirus disease 2019 (COVID-19) is unclear. The study evaluated the relationship between the vaccination status and risk factors in the re-infection of patients with a diagnosis of COVID-19 who reported to the Public Health Management System in a province in south-eastern Turkey. Methods Patients with positive results for the severe acute respiratory syndrome coronavirus 2 by the real-time reverse transcription polymerase chain reaction (RT-PCR) test in respiratory samples were defined as confirmed cases. Reinfection was diagnosed in cases with COVID-19 real-time RT-PCR positivity, with or without COVID-19-like symptoms, in at least 90 days after the first infection/disease. Results A total of 58 811 patients with the diagnosis of COVID-19 from March 11, 2020, to August 31, 2021, were included in the study. Re-infection was detected in 421 (0.07%) of all patients. The mean age of the cases was 38.0 +/- 16.0 years, and 51% of them were female. Eight (2.0%) of the cases resulted in death due to re-infection. No hospitalization or mortality was observed in fully vaccinated patients. Additionally, none of the mortal cases had completed the vaccination schedule. Conclusions We are concerned that the re-infection rates and mortality may increase due to new variant strains. Vaccination is the greatest weapon against progression to critical illness in re-infections, even with existing mutations. Therefore, it is important for those without a full vaccination schedule to be vaccinated, even if they have been previously infected.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume52
dc.identifier.doi10.1111/eci.13767
dc.identifier.eissn1365-2362
dc.identifier.issn0014-2972
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85127245521
dc.identifier.urihttp://dx.doi.org/10.1111/eci.13767
dc.identifier.urihttps://hdl.handle.net/20.500.14288/17171
dc.identifier.wos772990000001
dc.keywordsCoronavirus
dc.keywordsCOVID-19
dc.keywordsRe-infection
dc.keywordsSARS-CoV-2
dc.keywordsVaccination SARS-COV-2
dc.languageEnglish
dc.publisherWiley
dc.sourceEuropean Journal of Clinical Investigation
dc.subjectMedicine
dc.subjectGeneral Internal
dc.subjectMedicine
dc.subjectResearch Experimental
dc.titleRe‐infection in COVID‐19: Do we exaggerate our worries?
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0001-9419-8713
local.contributor.kuauthorTekin, Süda

Files